Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors

Adenovirus-based gene transfer vectors are the most frequently used vector type in gene therapy clinical trials to date, and they play an important role as genetic vaccine candidates during the ongoing SARS-CoV-2 pandemic. Immediately upon delivery, adenovirus-based vectors exhibit multiple complex vector-host interactions and induce innate and adaptive immune responses. This can severely limit their safety and efficacy, particularly after delivery through the blood stream. In this review article we summarize two strategies to modulate Ad vector-induced immune responses: extensive genomic and chemical capsid modifications. Both strategies have shown beneficial effects in a number of preclinical studies while potential synergistic effects warrant further investigations.

• Publication year

  2021

• Venue

  International Journal of Molecular Sciences

• Publication date

  2021-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ijms22052417PMID 33670859PMCID 7957472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

  2021cited by this paper
• Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

  2020cited by this paper
• Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

  2020cited by this paper
• Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

  2020cited by this paper
• Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

  2020cited by this paper
• Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control

  2018cited by this paper
• Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity.

  2016cited by this paper
• Adenoviral vector-based strategies against infectious disease and cancer

  2016cited by this paper
• Adenovirus Composition, Proteolysis, and Disassembly Studied by In-depth Qualitative and Quantitative Proteomics*

  2014cited by this paper
• Traceless Bioresponsive Shielding of Adenovirus Hexon with HPMA Copolymers Maintains Transduction Capacity In Vitro and In Vivo

  2014cited by this paper
• Transgene Expression up to 7 Years in Nonhuman Primates Following Hepatic Transduction with Helper-Dependent Adenoviral Vectors

  2013cited by this paper
• Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement

  2013cited by this paper
• Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity

  2012cited by this paper
• Serotype-Specific Neutralizing Antibody Epitopes of Human Adenovirus Type 3 (HAdV-3) and HAdV-7 Reside in Multiple Hexon Hypervariable Regions

  2012cited by this paper
• High‐capacity adenoviral vectors circumvent the limitations of ΔE1 and ΔE1/ΔE3 adenovirus vectors to induce multispecific transgene product‐directed CD8 T‐cell responses

  2011cited by this paper
• Adenovirus Serotype 5 Neutralizing Antibodies Target both Hexon and Fiber following Vaccination and Natural Infection

  2011cited by this paper
• Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors

  2011cited by this paper
• Helper-Dependent Adenoviral Vectors.

  2011cited by this paper
• Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.

  2011cited by this paper
• Atomic Structure of Human Adenovirus by Cryo-EM Reveals Interactions Among Protein Networks

  2010cited by this paper
• Crystal Structure of Human Adenovirus at 3.5 Å Resolution

  2010cited by this paper
• Capsomer-Specific Fluorescent Labeling of Adenoviral Vector Particles Allows for Detailed Analysis of Intracellular Particle Trafficking and the Performance of Bioresponsive Bonds for Vector Capsid Modifications

  2010cited by this paper
• Comparison of Replication-Competent, First Generation, and Helper-Dependent Adenoviral Vaccines

  2009cited by this paper
• Antiviral Antibodies Target Adenovirus to Phagolysosomes and Amplify the Innate Immune Response1

  2009cited by this paper
• Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.

  2009cited by this paper
• Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere.

  2008cited by this paper
• Activation of a dendritic cell–T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells

  2008cited by this paper
• The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens.

  2008cited by this paper
• Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies.

  2008cited by this paper
• Effects of Shielding Adenoviral Vectors with Polyethylene Glycol on Vector-Specific and Vaccine-Mediated Immune Responses

  2008cited by this paper
• Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

  2007cited by this paper
• Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.

  2007cited by this paper
• Innate immune recognition of viral infection.

  2006cited by this paper
• Innate immune recognition of viral infection

  2006cited by this paper
• Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting.

  2006cited by this paper
• Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system.

  2006cited by this paper
• Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

  2006cited by this paper
• Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins.

  2006cited by this paper
• Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses.

  2005cited by this paper
• Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naïve and pre-immunized mice

  2005cited by this paper
• Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1

  2005cited by this paper
• Neutrophils Interact with Adenovirus Vectors via Fc Receptors and Complement Receptor 1

  2005cited by this paper
• Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector.

  2005cited by this paper
• Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors.

  2005cited by this paper
• TLR9 signals after translocating from the ER to CpG DNA in the lysosome

  2004cited by this paper
• China approves first gene therapy

  2004cited by this paper
• Helper-Dependent Adenovirus Vectors Elicit Intact Innate but Attenuated Adaptive Host Immune Responses In Vivo

  2004cited by this paper
• Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors

  2004cited by this paper
• The interface between innate and adaptive immunity

  2004cited by this paper
• Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies.

  2004cited by this paper
• Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus

  2004cited by this paper
• Acute Toxicity After High-Dose Systemic Injection of Helper-Dependent Adenoviral Vectors into Nonhuman Primates

  2004cited by this paper
• Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL

  2004cited by this paper
• Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.

  2003cited by this paper
• Identification of Adenovirus (Ad) Penton Base Neutralizing Epitopes by Use of Sera from Patients Who Had Received Conditionally Replicative Ad (Addl1520) for Treatment of Liver Tumors

  2003cited by this paper
• Titer determination of Ad5 in blood: a cautionary note

  2003cited by this paper
• Structural and Phylogenetic Analysis of Adenovirus Hexons by Use of High-Resolution X-Ray Crystallographic, Molecular Modeling, and Sequence-Based Methods

  2003cited by this paper
• Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B.

  2002cited by this paper
• The Adenovirus Capsid Protein Hexon Contains a Highly Conserved Human CD4+ T-Cell Epitope

  2002cited by this paper
• Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

  2002cited by this paper
• PEGylation of E1-Deleted Adenovirus Vectors Allows Significant Gene Expression on Readministration to Liver

  2002cited by this paper
• Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.

  2002cited by this paper
• Bacterial CpG‐DNA and lipopolysaccharides activate Toll‐like receptors at distinct cellular compartments

  2002cited by this paper
• Adenovirus Vector-Induced Inflammation: Capsid-Dependent Induction of the C-C Chemokine RANTES Requires NF-κB

  2002cited by this paper
• Preexisting Immunity to Adenovirus in Rhesus Monkeys Fails To Prevent Vector-Induced Toxicity

  2002cited by this paper
• Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

  2001cited by this paper
• Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector

  2001cited by this paper
• Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies

  2001cited by this paper
• “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung

  2001cited by this paper
• Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

  2001cited by this paper
• Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.

  2001cited by this paper
• Blood clearance rates of adenovirus type 5 in mice.

  2000cited by this paper
• Toll-like receptors in the induction of the innate immune response

  2000cited by this paper
• Adenovirus Vector-Induced Expression of the C-X-C Chemokine IP-10 Is Mediated through Capsid-Dependent Activation of NF-κB

  2000cited by this paper
• Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in Vivo

  1999cited by this paper
• PEGylation of Adenovirus with Retention of Infectivity and Protection from Neutralizing Antibody in Vitro and in Vivo

  1999cited by this paper
• Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.

  1999cited by this paper
• Effects of Stuffer DNA on Transgene Expression from Helper-Dependent Adenovirus Vectors

  1999cited by this paper
• Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted

  1998cited by this paper
• Production and Characterization of Improved Adenovirus Vectors with the E 1 , E 2 b , and E 3 Genes Deleted

  1998cited by this paper
• Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector.

  1997cited by this paper
• A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging

  1997influential reference
• The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors

  1997cited by this paper
• Effect of the E4 region on the persistence of transgene expression from adenovirus vectors

  1997cited by this paper
• Immune responses to transgene–encoded proteins limit the stability of gene expression after injection of replication–defective adenovirus vectors

  1996cited by this paper
• Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs

  1996cited by this paper
• Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy

  1996cited by this paper
• MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

  1994cited by this paper
• Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

  1994cited by this paper
• Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

  1994cited by this paper
• Packaging capacity and stability of human adenovirus type 5 vectors

  1993cited by this paper
• Antipeptide antisera define neutralizing epitopes on the adenovirus hexon.

  1992cited by this paper
• The uses and properties of PEG-linked proteins.

  1992cited by this paper
• Worldwide epidemiology of human adenovirus infections.

  1983cited by this paper

• Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations.

  2026cites this paper
• Photobiomodulation of Blue Light Enhance Melanoma Cellular Recovery Following Viral Infection via Mitochondrial Pathways

  2025influential citation
• The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches

  2025influential citation
• Adenoviral Therapy for Cervical Cancer: From Targeted Modification to Immunotherapy.

  2025cites this paper
• Adeno-associated virus (AAV)-TBX18 does not generate biological pacemaker activity, unlike AAV-Hcn2

  2025cites this paper
• Modern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics

  2025cites this paper
• CRISPR Delivery Systems for Organ-Specific Targeting: Advances and Challenges

  2025cites this paper
• Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases

  2024cites this paper
• Challenges and progress related to gene editing in rare skin diseases.

  2024cites this paper
• Innate Immune Response to Viral Vectors in Gene Therapy

  2023cites this paper
• Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells

  2023cites this paper
• Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity

  2023influential citation
• Basic Principles of RNA Interference: Nucleic Acid Types and In Vitro Intracellular Delivery Methods

  2023cites this paper
• An Optimized CRISPR/Cas9 Adenovirus Vector (AdZ-CRISPR) for High-Throughput Cloning of sgRNA, Using Enhanced sgRNA and Cas9 Variants

  2022cites this paper
• The Immune Response, Safety, and Efficacy of Emergency Use Authorization-Granted COVID-19 Vaccines: A Review

  2022cites this paper
• Viral Vector Vaccines Against ASF: Problems and Prospectives

  2022cites this paper
• Linking digital surveillance and in-depth virology to study clinical patterns of viral respiratory infections in vulnerable patient populations

  2022cites this paper
• Episomes and Transposases—Utilities to Maintain Transgene Expression from Nonviral Vectors

  2022cites this paper
• MicroRNAs in T Cell-Immunotherapy

  2022cites this paper
• PLATELETS Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

  2021cites this paper
• Vector Strategies to Actualize B Cell–Based Gene Therapies

  2021cites this paper
• Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

  2021cites this paper
• Use of lentiviral vectors in vaccination

  2021cites this paper
• Delivery of Anti-IFNAR1 shRNA to Hepatic Cells Decreases IFNAR1 Gene Expression and Improves Adenoviral Transduction and Transgene Expression

  2021cites this paper
• Current development in adenoviral vectors for cancer immunotherapy.

  2021cites this paper
• Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy

  2021cites this paper
• Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties

  2021cites this paper